Keyword: Kevzara (sarilumab)
Sanofi and Regeneron may have had a successful year with Dupixent—approved in March to treat atopic dermatitis—but there's much more to come.
Could Dupixent end up beating Novartis’ Cosentyx on launch trajectory? The numbers are looking that way so far, a Sanofi executive said Monday.
Eli Lilly’s RA med baricitinib had been pegged as one of 2017’s hottest launches—and a threat to Pfizer’s Xeljanz. Not anymore.
Eli Lilly has won a nod from NICE for its anticipated blockbuster and Humira competitor, Olumiant, a drug the FDA rejected in April.
Halfway into 2017, the FDA has beaten last year's drug-approvals tally with a crop featuring controversy, sales firepower and one very high price.
With biologics dominating its pipeline, Sanofi will spend as much as $2 billion on its biologics manufacturing network over the next several years.
Sanofi and Regeneron just added their second building block to a nascent immunology franchise expected to bring in $5 billion or more by 2022.
Regeneron’s flagship med Eylea fell short of sales expectations in Q1, raising questions as Praluent idles and potential big-earner Dupixent makes its debut.
Sanofi CEO Olivier Brandicourt has been criticized for failing to pull off a couple of big acquisitions, but his more mundane deal to get Boehringer Ingelheim’s consumer health business helped it turn in a surprisingly strong Q1.